Skip to content

Observation of the efficacy and regulatory mechanism of Jingfang granules in postoperative non-infectious fever in patients undergoing abdominal surgery

Observation of the efficacy and regulatory mechanism of Jingfang granules in postoperative non-infectious fever in patients undergoing abdominal surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500100528
Enrollment
Unknown
Registered
2025-04-10
Start date
2025-04-30
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

After surgery Noninfectious fever

Interventions

Jingfang granule group:Within 48 hours after surgery, Jingfang granules were given oral or gastric tube nasogastric feeding, 15g once, 3 times a day, for 7 days
Physical cooling group:Alcohol swabs and acetaminophen drugs are given in addition to conventional treatment
No fever group:No

Sponsors

The Second Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for non-infectious fever: (1) normal preoperative body temperature, (2) body temperature >= 37.5 °C and =18 years old and <= 80 years old, no contraindications to surgery, and in the perioperative period; 3. Patients with hepatobiliary and pancreatic surgery undergoing laparotomy and fourth-level laparoscopic surgery; 4. Patients with no serious medical diseases, no mental illnesses, no history of major surgery, and no serious postoperative complications; 5. Those who have good compliance, voluntarily participate in this study and sign the informed consent form, and are able to cooperate with the completion of the outcome index assessment.

Exclusion criteria

Exclusion criteria: 1. Women who are pregnant or preparing to become pregnant or lactating; 2. Those with allergies or a history of allergies to this test method; 3. Patients who are currently participating in other clinical trials; 4. Patients who are unable to take medication regularly due to complications and other conditions after surgery; 5. Patients with poor postoperative compliance and expected to be difficult to follow up normally; 6. Patients who are unable to tolerate the drug, or have large side effects, and give up participating in clinical trials;

Design outcomes

Primary

MeasureTime frame
Body temperature;

Secondary

MeasureTime frame
Haemoglobin;Serum albumin;

Countries

China

Contacts

Public ContactChongzhongLiu

The Second Hospital of Shandong University

lczk1980@163.com+86 531 8587 5602

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026